Published online Dec 21, 2013. doi: 10.3748/wjg.v19.i47.8963
Revised: November 7, 2013
Accepted: November 18, 2013
Published online: December 21, 2013
Processing time: 113 Days and 18.2 Hours
Core tip: Understanding the effectiveness and affecting factors of antiviral regimens are critical for making informed treatment decisions for hepatitis C virus (HCV) infection. In this review, we have summarized the history of anti-HCV agents from interferon to the direct-acting antiviral drugs (DAAs) without polyethylene glycol interferon-α therapies and the affecting factors of antiviral treatment, focusing on investigating the optimal combination of antiviral therapies to achieve higher efficacy and better medication compliance. Although the efficacy of DAAs is significantly improved, many unmet needs and questions remain, such as avoidance of cross-resistance, the remaining high incidence of side effects, the role of IL28B status as well as the management of patients who do not respond to therapy.